Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

New Year's Resolution: Let It Go—AJR Podcast Series on Wellness, Episode 10
Wang, Sherry S.

Mayo Clinic

American Journal of Roentgenology | January 8, 2025 | Volume: 224 | Issue: 2 | Pages: No page available

10.2214/ajr.24.32580 | PMID 39772577 Get It

NPA7: A Dual Receptor Activating Peptide That Inhibits Cardiac Oxidative Stress
Ma, Xiaoyu , Malsawmzuali, JC, Moroni, Dante , Ma, Xiao, Zheng, Ye , Pan, Shuchong, Wang, Ying , Sangaralingham, S. Jeson , Burnett, J. C., Malsawmzuali, JC , Malsawmzuali, Joute Chawngvawr, Moroni, Dante G , Wang, Ying , Malsawmzuali, J C , Sangaralingham, S. Jeson

Mayo Clinic

Hypertension | January 8, 2025 | Volume: 82 | Issue: 3 | Pages: 463-475

10.1161/hypertensionaha.124.23579 | PMID 39772591 Get It

BACKGROUND: Cardiomyocyte oxidative stress significantly contributes to the progression of hypertension-induced heart failure, highlighting the need for targeted therapies. We developed a novel peptide, NPA7, that coactivates the GC-A (guanylyl cyclase A)/cGMP and MasR (Mas receptor)/cAMP pathway. This study aimed to test NPA7’s ability to inhibit oxidative stress by modulating the p62 (Sequestosome 1)-KEAP1 (Kelch-like ECH-associated protein 1)-NRF2 (nuclear factor erythroid 2-related factor 2) pathway in human cardiomyocytes (HCMs) and a rat model of hypertension. METHODS: Oxidative stress was induced in HCMs using H 2 O 2 with phosphate-buffered saline or NPA7 treatment. Intracellular reactive oxygen species levels were assessed via dihydroethidium staining. Western blotting analysis measured p62, KEAP1, and NRF2 protein levels, while GSH/GSSG (glutathione/glutathione disulfide) ratios and antioxidant gene expression were analyzed. HCMs were transfected with small interfering RNA targeting GC-A, MasR, or p62 before NPA7 and H 2 O 2 treatment. In vivo, spontaneously hypertensive rats received saline or NPA7, with normotensive Wistar Kyoto rats as control and cardiac oxidative stress, KEAP1 protein levels, NOX2 (NADPH oxidase 2), and p67 (NADPH oxidase subunit p67-phox) mRNA levels were measured. RESULTS: NPA7 reduced H 2 O 2 -induced reactive oxygen species levels and increased GSH/GSSG ratio in HCMs. Silencing GC-A (guanylyl cyclase A receptor) and MasR (Mas receptor) reversed NPA7’s effects. NPA7 activated the KEAP1-NRF2 pathway, enhancing NRF2’s antioxidant target gene expression. In p62 knockdown HCMs, NPA7-induced KEAP1 degradation and NRF2 activation were diminished. Reactive oxygen species levels were elevated in spontaneously hypertensive rat versusWistar Kyoto rats’ hearts, however, NPA7 treatment reduced myocardial reactive oxygen species, suppressed KEAP1 protein, and decreased NOX2 and p67 mRNA levels. CONCLUSIONS: NPA7 exhibits antioxidant properties in HCMs and spontaneously hypertensive rat hearts by targeting GC-A and MasR through the p62-KEAP1-NRF2 pathway, supporting a novel therapeutic approach against cardiovascular disease–related oxidative stress.
Survival benefit associated with liver transplantation for hepatocellular carcinoma based on tumor burden scores at listing
Liu, Hao , Lee, Hang , Shi, Liuhua , Wang, Xixi , Powers, Colin , Li, Xingjie , Alberola, Ramon Bataller, Behari, Jaideep , Duarte‐Rojo, Andrés , Hughes, Dempsey L. , Malik, Shahid M. , Jonassaint, Naudia , Tohme, Samer , Gunabushanam, Vikraman , Tevar, Amit D. , Cruz, Ruy J. , Dharmayan, Stalin, Ayloo, Subhashini, Humar, Abhinav , Liu, Hao , Duarte-Rojo, Andres , Zhang, Wei , Di, Mengyang , Wang, Xixi, Zhang, Xingyu , Sethi, Vrishketan , Xiao, Yao , Crane, Andrew, Kaltenmeier, Christof , Geller, David A. , Hughes, Christopher L. , Molinari, Michele

Mayo Clinic

Hepatology Communications | January 7, 2025 | Volume: 9 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000619 | PMID 39774957 Get It

Introduction: Liver transplantation (LT) provides significant survival benefits to patients with unresectable HCC. In the United States, organ allocation policies for HCCs within the United Network for Organ Sharing criteria do not prioritize patients based on their differences in oncological characteristics. This study assessed whether transplant-associated survival benefits (TASBs) vary among patients with different tumor burden scores (TBS) measured at the time of listing. Methods: We analyzed data from adults applying for HCC MELD exception points between 2002 and 2019, with follow-up until December 2023, using the Scientific Registry of Transplant Recipients. TBS was determined based on the largest tumor diameter and number of HCCs. Patients were categorized into low (≤3), intermediate (3.1–5), and high (>5) TBS groups. TASB was measured as the difference in 5-year survival with and without LT. Results: This study included 36,634 LT candidates. High-TBS patients had higher waitlist dropout rates and marginally lower post-transplant survival, resulting in a significantly greater TASB. The 5-year TASB for the low, intermediate, and high TBS groups were 15.7, 22.1, and 25.0 months, respectively. The adjusted survival benefit expressed in 5-year survival differences was 21.9%, 34.5%, and 39.4% in the low, intermediate, and high TBS groups, respectively ( p <0.001). Conclusions: Higher TBS during listing correlates with greater LT benefits for patients with unresectable HCC within UNOS criteria. We conclude that organ allocation policies in the United States should prioritize patients with high TBS due to their increased risk of dropout and comparable post-transplant survival when compared to patients with less advanced tumors.
Correlation of the Sinonasal Outcome Test‐22 With the University of Washington Quality of Life in Assessing Quality of Life in Sinonasal Malignancy Utilizing a Multicenter Prospective Observational Cohort Registry
Fleseriu, Cara M. , Beswick, Daniel M. , Maoz, Sabrina L. , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Traylor, Katie , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Patel, Zara M. , Smith, Timothy L. , Wang, Marilene B. , Wang, Eric W , Beswick, Daniel , Maoz, Sabrina L , Hwang, Peter H , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Adappa, Nithin D. , Geltzeiler, Mathew , Abuzeid, Waleed M. , Pinheiro‐Neto, Carlos , Le, Christopher H. , Lee, Jivianne K., Nayak, Jayakar V. , John, Maie A. St. , Suh, Jeffrey D. , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | January 6, 2025 | Volume: 15 | Issue: 4 | Pages: 451-454

10.1002/alr.23522 | PMID 39761380 Get It

Towards H&E Referenced Multiplex Immunofluorescence Interpretation: Spatial Co-localization, Cell Feature Validation, and Virtual H&E Generation
Wang, Chen , Moore, Raymond M. , Novotny, Brenna C. , Guo, Ruifeng , Fogarty, Zachary C. , Liu, Yuanhang , Goode, Ellen L. , Winham, Stacey J. , Markovic, Svetomir N. , Jiang, Jun , Novotny, Brenna , Guo, Ruifeng , Fogarty, Zachary C , Goode, Ellen L , Winham, Stacey J , Markovic, Svetomir , Wang, Chen , Jiang, Jun

Mayo Clinic

No container title available | January 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5619126/v1 | PMID 39866878 Get It

Abstract Multiplexed Immunofluorescence (MxIF) enables detailed immune cell phenotyping, providing critical insights into cell behavior within the tumor immune microenvironment (TIME). However, signal integrity can be compromised due to the complex cyclic staining processes inherent to MxIF. Hematoxylin and Eosin (H&E) staining, on the other hand, offers complementary information through its depiction of cell morphology and texture patterns and is often visually cross-referenced with MxIF in clinical settings. In this study, we proposed a novel framework to align H&E and MxIF images for precise cross-modal cell feature validation. Using cell detection outputs from each modality as anchors, we formulated the multimodal image registration problem as point set alignment. Coherent Point Drift (CPD) is employed for initial alignment, followed by Graph Matching (GM) for refinement. Evaluations on ovarian cancer tissue microarrays (TMAs) demonstrate that our method achieves high alignment accuracy, enabling reliable validation of cell-level features across modalities for both restained and serial sections. Our results indicate that restained H&E enhances confidence in findings derived from MxIF. Additionally, we demonstrated the feasibility of generating high-quality virtual H&E images from MxIF data when restained H&E is unavailable, offering a viable alternative for integrated multimodal analysis.
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
Young, Ken H. , Jia, Youchao, Tzankov, Alexandar , Go, Heounjeong , Li, Ling , Zhai, Qiong-Li , Perry, Anamarija M. , Wang, Shi , Wang, Xiaoxiao , Chiu, April , Xu, Mina L. , Visco, Carlo , Yuan, Alyssa F. , Miao, Yi , Li, Jianyong , Shuai, Wen , Wang, Bangchen , Pan, Zenggang , Chen, Weina , Zhang, Shanxiang , Sohani, Aliyah R. , Ferreri, Andrés J.M. , Xu, Bing , Young, Ken H , Tzankov, Alexandar , Go, Heounjeong , Xu, Mina , Dybkaer, Karen , Withers, Henry , Li, Jianyong , Bhagat, Govind , Chen, Weina , Møller, Michael Boe , Zhan, Fenghuang , Sohani, Aliyah , Ferreri, Andrés J M , Xu, Bing , Li, Yong , Wang, Bangchen , Shi, Wenyu , Xu‐Monette, Zijun Y. , Ponzoni, Maurilio , Wang, Yafei , Dybkær, Karen , Long, Mark D. , Macias, Everardo , Bhagat, Govind , Zu, Youli , Choi, William, Montes‐Moreno, Santiago , Krieken, J. Han van , Møller, Michael , Zhan, Fenghuang , Parsons, Benjamin M. , Hsi, Eric D. , Abramson, Jeremy S. , Li, Yong

Mayo Clinic

No container title available | January 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5732026/v1 | PMID 39866884 Get It

Abstract Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive lymphoma with molecular heterogeneity not well characterize. In this study, we performed next-generation sequencing analysis for a large number of DNA and RNA samples from patients with PT-DLBCL. DNA sequencing analysis identified ≥ 3 chromosomes with copy number variations (CNVs) and microsatellite instability as prognostic biomarkers, rather than MYD88 mutations and genetic subtypes. Remarkably, targeted RNA-seq analysis in 195 patients revealed that TP53 mutations with a ≥ 40% variant allele frequency had significantly adverse prognostic impact, and that a 150-gene expression signature subdivided PT-DLBCL into two distinct clusters, termed as testicular lymphoma tumor (TLT) and microenvironment (ME) subtypes. The TLT subtype featured upregulation of genes involved in B-cell receptor signaling, cell cycle, DNA damage and repair, higher frequencies of CNVs and MYD88 mutations, elder ages, larger tumor sizes, and significantly poorer survival. Genomic microRNA profiling analysis identified significantly differentially expressed microRNAs between 113 PT-DLBCL and 180 systemic DLBCL patients, and further subdivided the PT-DLBCL cohort by microRNA signatures. The subcohort with upregulation of 16 microRNAs associated with PT-DLBCL and testicular tissue expression had significantly better survival. This study revealed characteristic genetic, gene expression, and microRNA profiles and heterogeneity in PT-DLBCL.
SNP rs9364554 Modulates Androgen Receptor Binding and Drug Response in Prostate Cancer
Yan, Yuqian , Ma, Tao , Wang, Liguo , Wang, Liguo , Shi, Lei , Huang, Haojie

Mayo Clinic

Biomolecules | January 6, 2025 | Volume: 15 | Issue: 1 | Pages: 64

10.3390/biom15010064 | PMID 39858458 Get It

(1) Background: Prostate cancer treatment efficacy is significantly influenced by androgen receptor (AR) signaling pathways. SLC22A3, a membrane transporter, has been linked to SNP rs9364554 risk loci for drug efficacy in prostate cancer. (2) Methods: We examined the location of SNP rs9364554 in the genome and utilized TCGA and other publicly available datasets to analyze the association of this SNP with SLC22A3 transcription levels. We verified onco-mining findings in prostate cancer cell lines using quantitative PCR and Western blots. Additionally, we employed electrophoretic mobility shift assay (EMSA) to detect the binding affinity of transcription factors to this SNP. The ChIP-Seq was used to analyze the enrichment of H3K27ac on the SLC22A3 promoter. (3) Results: In this study, we revealed that SNP rs9364554 resides in the SLC22A3 gene and affects its transcription. The downregulation of SLC22A3 is associated with drug resistance. More importantly, we found that this SNP has different binding affinities with transcription factors, specifically FOXA1 and AR, which significantly affects their regulation of SLC22A3 transcription. (4) Conclusions: Our findings highlight the potential of using this SNP as a biomarker for predicting chemotherapeutic outcomes and uncover possible mechanisms underlying drug resistance in advanced prostate cancers. More importantly, it provides a clinical foundation for targeting FOXA1 to enhance drug efficacy in prostate cancer patients.
Preserved transcriptional networks in immune signaling pathways associated with chronic disease identified in Alzheimer’s disease and Parkinson’s disease, cross‐tissue analysis
Strickland, Samantha L. , Tsai, Wei, Chen, Xuan , Cherukuri, Yesesri , Allen, Mariet , Quicksall, Zachary , Wang, Xue , Carrasquillo, Minerva M. , Nho, Kwangsik, Petersen, Ronald C., Reddy, Joseph S. , Ertekin‐Taner, Nilüfer , Kantarci, Kejal , Carrasquillo, Minerva M. , Saykin, Andrew J. , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.092349 Get It

AbstractBackgroundSystemic inflammation plays a pivotal role in many chronic diseases including Alzheimer’s disease (AD). Assessing the composition of immune pathways in neurodegenerative diseases can contribute to precision medicine. Using publicly available transcriptomic data, we sought to elucidate transcriptional networks pertinent to inflammatory pathways across brain regions and peripheral blood in AD/mild cognitive impairment (MCI) and peripheral blood in Parkinson’s disease (PD).MethodFor the AD/MCI vs. control dataset, we analyzed bulk‐RNAseq collected from 6 brain regions of donors from ROSMAP, Mayo Clinic, and Mount Sinai School of Medicine (MSSM) brain banks available from the AMP‐AD consortium. Ante‐mortem, blood RNAseq expression data was retrieved from the AMP‐AD Emory Vascular cohort and Mayo Clinic Study of Aging (MCSA). We also collected blood‐derived microarray expression data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). For the PD vs Control dataset, blood‐derived bulk‐RNAseq from the PDBP and PPMI cohorts were available through the AMP‐PD consortium. Following quality control, normalization, and residual generation to account for biological and technical variables, co‐expression network modules and their enriched pathways were identified using WGCNA within each dataset. Module/trait correlation tests for aging and diagnosis (cases [AD/MCI or PD] vs control) phenotypes were evaluated. Gene Ontology enrichment analyses were executed to identify enriched pathways and brain or blood cell types within the modules. Modules were tested for preservation across cohorts.ResultWe identified conserved immune signatures across brain regions and cohorts. Modules involved in immune response were preserved across all cohorts. Blood consensus modules involved in immune response were preserved in the brain and vice versa. Some immune modules were associated with AD/MCI, PD, and/or aging. Brain immune modules are significantly associated with aging and/or AD. Significant correlations (q<0.05) with PD diagnosis were present. In the MCSA and Emory vascular cohorts, there were no significant (q<0.05) associations between modules and diagnosis, while in ADNI there were nominal (p<0.05) associations.ConclusionPreserved transcriptional immune networks were identified across blood and brain and across two neurodegenerative diseases. Expanding gene co‐expression network analyses to other diseases and integrating additional omics measures and phenotypes can further strengthen these findings to unravel the immune signatures across complex diseases.
Integrative approach to profile resilience and risk factors in Alzheimer’s disease
İş, Özkan , Is, Ozkan, Bergman, Jeremiah, Xue, Wang , Tutor‐New, Frederick Q, Quicksall, Zachary , Atık, Merve, Reddy, Joseph S. , Duvuuri, Venkata N.S., Min, Yuhao , Gao, Junli , Sotelo, Katie D., Nguyen, Thuy , Allen, Mariet , Ertekin‐Taner, Nilüfer , Is, Ozkan, Wang, Xue, Duvuuri, Venkata Naga Sreelalitapriya , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.091859 Get It

AbstractBackgroundA complex, multicellular disease with genetic and immunological elements, Alzheimer’s disease (AD) affects millions worldwide. There has been previous research linking AD to the missense variants ABI3‐rs616338‐T and PLCG2‐rs72824905‐G, and the altered expression of these genes has been shown to disrupt microglial function. In our understanding of AD risk and resilience, limited research has been conducted on how these variants affect microglial subtypes and states in AD.MethodsWe previously identified DOCK8 protein as a target for fluorescent activated nuclei sorting (FANS) to enrich microglia nuclei from frozen human brains. Using this enrichment strategy, we generated microglia enriched snRNAseq data from temporal cortex tissue of 30 donors harboring ABI3 or PLCG2 missense mutations, or neither mutation. We introduced PLCG2 variant in either homozygote, and heterozygote forms into an AD patient derived iPSC through CRISPR/Cas9 approach, differentiated these cells into microglia cells (IMGLs) following established protocols, and generated scRNAseq data after treatment with Amyloidβ. We applied standard alignment and quality control pipelines to the snRNAseq and scRNAseq datasets in parallel. Established markers of microglia states and subtypes were utilized to annotate the clusters; analyzed for their hub gene expression using comparisons between cluster differential profiling to determine signature pathways. Differential gene expression was assessed using pseudo bulk and MAST approaches.ResultsWe obtained single nuclei transcriptome profiles of 54,000 frozen human brain nuclei, of which 35,000 are microglia, through snRNAseq, and single cell profiles of 63,000 iMGLs through scRNAseq, using our standard alignment and quality control procedures. Our differential gene expression analysis identified novel genes and pathways which were identified as part of resilience or AD risk networks in microglia subtypes and states. These alterations were validated using orthogonal experimental methods and further explored for their conservation using in vivo external datasets. Pseudotime inference will be completed to probe microglia marker gene expression dynamics, treatment conditions, along with continuous cell‐state changes.ConclusionOur study uncovers microglia subtype specific resilience and risk factors provided by AD related genetic variants using snRNAseq from frozen human brain and scRNAseq from IPSC derived microglia cells. These findings nominate novel targets and pathways with therapeutic potential.
Multi‐omics profiling of Alzheimer’s disease in multi‐ethnic populations
Reddy, Joseph S. , Allen, Mariet , Poehlman, William L. , Wang, Yanling , Johnson, Ryan , Ho, Charlotte C.G. , Linden, Abby Vander , Quicksall, Zachary , Chen, Xianfeng , Baheti, Saurabh , Nguyen, Thuy , Yepez‐Sisalema, Geovanna, Mitchell, Adriana O., Oatman, Stephanie R., Wang, Xue , Carrasquillo, Minerva M. , Beach, Thomas G., Golde, Todd E. , Haroutunian, Vahram , Jager, Philip L. De , Bennett, David A. , Seyfried, Nicholas T. , Ertekin‐Taner, Nilüfer , Initiative, Accelerating Medicines Partnership for Alzheimer’s Disease (AMP‐AD) Diversity, Heath, Laura , Johnson, Ryan, Wang, Erming , Ma, Yiyi , Lopes, Kátia de Paiva , Wang, Xue, Carrasquillo, Minerva M. , Runnels, Alexi , Teich, Andrew F. , Beach, Thomas G. , Serrano, Geidy E. , Barnes, Lisa L. , Wang, Minghui , Zhang, Bin , Greenwood, Anna, Initiative, Accelerating Medicines Partnership for Alzheimer’s Disease (AMP‐AD) Diversity

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.090590 Get It

AbstractBackgroundAlzheimer’s disease (AD) is a devastating neurodegenerative disorder with few therapies to treat, mitigate or prevent its onset. Understanding of this disease is predominantly based on research in non‐Hispanic Whites (NHW) although AD disproportionately affects African Americans (AA) and Latin Americans (LA), underrepresented in AD research. To address this knowledge gap, the Accelerating Medicine Partnership for Alzheimer’s Disease (AMP‐AD) Diversity Working Group was launched to generate multi‐omics data from post‐mortem brain tissue from donors of predominantly AA and LA descent. Here, we focus on genomic and transcriptomics measures, made available through the AD Knowledge Portal (ADKP).MethodBrain tissue from dorsolateral prefrontal cortex (DLPFC), caudate nucleus (CN), superior temporal gyrus (STG) and temporal pole (TP) regions of AA (N = 299), LA (N = 344) and NHW (N = 532) donors was obtained through Mayo Clinic, Mt. Sinai School of Medicine, Emory, Columbia, Rush Alzheimer’s Disease Center, Banner Sun Health, and 1Florida. DNA extracted from DLPFC tissue samples (n = 641) was utilized for whole genome sequencing (WGS) at New York Genome Center (NYGC). RNAseq of 2,224 samples was conducted either at Mayo, Rush or NYGC. Sequencing reads were processed through GenomeGPS and MAPRseq pipelines for WGS and RNAseq data, respectively. Following quality control (QC), RNAseq data was normalized and assessed for sources of variation (SOV). Integration of WGS and RNAseq data to perform comparative eQTL analysis across multi‐ethnic populations and brain regions is ongoing.ResultWGS data for 621 donors, and RNAseq data generated at Mayo (n = 1,136 samples), Rush (n = 627), and NYGC (n = 779) sequencing centers, were deposited to the ADKP. Consensus processing of RNAseq data revealed site, sex, race/ethnicity, RIN, AD diagnosis, age at death and/or library batch as SOV across various sites and brain regions. Principal component analysis of gene expression measures revealed no major stratification by disease or brain region. Accompanying clinical metadata of donors have been distributed through ADKP.ConclusionThese multi‐omics data made available to the research community is expected to be an initial step towards bridging our data and knowledge gap to elucidate conserved and distinct AD related pathways across these underrepresented at‐risk populations.